Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visugromab in cancer-associated cachexia
NL-OMON61193Phase 3Not yet recruiting
- Sponsor
- CatalYm
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of visugromab in cancer anorexia-cachexia syndrome (CACS), sponsored by CatalYm. Primary endpoints: Change from baseline in body weight at 12 weeks and Change from baseline in appetite at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
visugromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NL-OMON61193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61193.